The provisionally approved digital health application optimuneforbreast cancer patients can no longer be prescribed on prescription since mid-July 2024. It appears as “deleted” in the DiGA directory.
In the price negotiations with the GKV-Spitzenverband , it emerged that the reimbursement price for oncological DiGA would be EUR 200 to 300 per prescription in future. This is not enough to cover the development and study costs, according to Dr. Mario Weiss, physician and CEO of GAIA AG. “After intensive consideration, we (…) have to recognize that the pricing conditions for DiGA do not allow a medium-sized company to carry out complex oncological research on a cost-covering basis.”
GAIA is one of the successful DiGA manufacturers with six products still listed in the DiGA directory.
